Your browser doesn't support javascript.
loading
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting.
Ikarashi, Daiki; Kitano, Shigehisa; Tsuyukubo, Takashi; Takenouchi, Kazumasa; Nakayama, Takayuki; Onagi, Hiroko; Sakaguchi, Asumi; Yamashita, Makiko; Mizugaki, Hidenori; Maekawa, Shigekatsu; Kato, Renpei; Kato, Yoichiro; Sugai, Tamotsu; Nakatsura, Tetsuya; Obara, Wataru.
Afiliación
  • Ikarashi D; Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
  • Kitano S; Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Tsuyukubo T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan.
  • Takenouchi K; Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan. shigehisa.kitano@jfcr.or.jp.
  • Nakayama T; Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
  • Onagi H; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan.
  • Sakaguchi A; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, 277-0872, Japan.
  • Yamashita M; Department of Human Pathology, Juntendo University School of Medicine, Tokyo, 113-0033, Japan.
  • Mizugaki H; Department of Human Pathology, Juntendo University School of Medicine, Tokyo, 113-0033, Japan.
  • Maekawa S; Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Kato R; Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-8550, Japan.
  • Kato Y; Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
  • Sugai T; Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
  • Nakatsura T; Department of Urology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
  • Obara W; Department of Pathology, Iwate Medical University School of Medicine, Iwate, 028-3695, Japan.
Br J Cancer ; 126(4): 606-614, 2022 03.
Article en En | MEDLINE | ID: mdl-34782748
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Linfocitos T CD8-positivos / Receptores Depuradores de Clase A Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Linfocitos T CD8-positivos / Receptores Depuradores de Clase A Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Japón